Understanding the GLP-1 Receptor Agonist Class: Where Tirzepatide Fits In

GLP-1 receptor agonists have transformed the treatment of type 2 diabetes and obesity. Here's a complete overview of the class and where tirzepatide fits in.

The GLP-1 Receptor Agonist Family

Currently Available GLP-1 RAs

Key Distinction: GLP-1 vs. Dual Agonist

While often grouped with GLP-1 agonists, tirzepatide is technically a GIP/GLP-1 dual receptor agonist. This distinction is important because:

• It's the only medication in its class
• The dual mechanism produces superior outcomes
• It represents a new therapeutic category

Evolution of the Class

First Generation (2005-2010)

• Exenatide (Byetta): First GLP-1 RA, twice daily
• Moderate efficacy, established safety profile

Second Generation (2010-2017)

• Liraglutide, dulaglutide: Daily/weekly options
• Improved efficacy and convenience
• Saxenda: First GLP-1 RA approved for weight loss

Third Generation (2017-2022)

• Semaglutide: Superior efficacy among GLP-1 agonists
• Oral formulation available
• Wegovy: High-dose for obesity

Fourth Generation (2022+)

• Tirzepatide: Dual agonist, highest efficacy
• Future agents: Triple agonists (GIP/GLP-1/glucagon), oral GLP-1 agonists, and more

Comparing Efficacy Across the Class

Weight Loss (in obesity trials)

• Liraglutide 3.0 mg: ~8% body weight
• Semaglutide 2.4 mg: ~15% body weight
• Tirzepatide 15 mg: ~22% body weight

HbA1c Reduction (in diabetes trials)

• Dulaglutide 4.5 mg: ~1.5%
• Semaglutide 1.0 mg: ~1.8%
• Tirzepatide 15 mg: ~2.4%

The Future of the Class

The GLP-1/incretin therapy space is rapidly evolving with new agents in development:

• Orforglipron: Oral GLP-1 agonist (Eli Lilly)
• Retatrutide: Triple agonist (GIP/GLP-1/glucagon) showing up to 24% weight loss
• Survodutide: GLP-1/glucagon dual agonist (Boehringer Ingelheim)
• CagriSema: Semaglutide + cagrilintide combination (Novo Nordisk)